Evidence mapPaperPMID 39899787Full record

ArticleNeurology2025

Cardiac Conduction Delay for Sodium Channel Antagonist Antiseizure Medications: An Analysis of the Canadian Longitudinal Study on Aging.

Nathan A Shlobin, Jimmy Li, Josemir W Sander, Mark Robert Keezer, Roland D Thijs

Abstract read
In one paragraph

Article in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nathan A ShlobinDepartment of Neurosurgery, Neurological Institute of New York, New York Presbyterian Hospital-Columbia University Medical Center, NY.ORCID 0000-0003-2079-6125
Jimmy LiCentre Hospitalier de l'Université de Sherbrooke (CHUS), Canada.ORCID 0000-0002-8386-8897
Josemir W SanderStichting Epilepsie Instellingen Nederland (SEIN), Heemstede, the Netherlands.ORCID 0000-0001-6041-9661
Mark Robert KeezerResearch Centre of the Centre Hospitalier de l'Université de Montréal (CRCHUM), Canada.ORCID 0000-0002-2807-7347
Roland D ThijsStichting Epilepsie Instellingen Nederland (SEIN), Heemstede, the Netherlands.ORCID 0000-0003-1435-8970

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesPeople with epilepsy are at risk of cardiac arrhythmias. Whether this association results from epilepsy, antiseizure medications (ASMs) such as sodium channel blockers (NABs), or other factors has not been systematically assessed. The aims of this study were to quantify the odds of cardiac conduction delays (CCDs) on electrocardiogram in older people with active epilepsy using vs not using NABs, to determine the prevalence of CCDs by NABs, and to examine the association of demographic and clinical factors with CCDs.

methodsThis was a cross-sectional study of the Canadian Longitudinal Study on Aging. We defined active epilepsy as self-reported epilepsy and taking ASM. Sodium channel blockers (NABs) were phenytoin, lamotrigine, carbamazepine, oxcarbazepine, or lacosamide. We compared CCDs between people with epilepsy using NABs and those not using NABs; determined the prevalence of CCDs by NAB type; and fitted a logistic regression model for each abnormal ECG outcome as a function of active epilepsy and NAB use while adjusting for demographics and clinical factors. Multiple imputations handled missing data (200 iterations).

resultsIn total, 30,077 people, with mean age 63.0 (10.25) years and 50.9% female, were studied, including 141 people with active epilepsy who used NABs, 68 who did not use NABs, and 29,868 who did not have active epilepsy. Demographics between groups and relative to people without epilepsy were similar. People with active epilepsy taking NABs were more likely to have prolonged QRS (odds ratio [OR] = 2.85 [95% CI 1.09-7.43]) and any CCD (1.94 [1.03-3.63]) compared with those with active epilepsy without NAB. After adjusting for Framingham score and heart rate-lowering medications, NAB use was associated with prolonged QTc (OR = 1.52 [95% CI 1.06-2.18]) and any CCD (1.78 [1.16, 2.74]). The prevalence of any CCD was 36.1% [95% CI 24.2%-49.4%] for carbamazepine, 45.5% [31.7%-58.5%] for phenytoin, and 54.7% [28.9%-75.6%] lamotrigine. Epilepsy was not associated with any CCD. DISCUSSION: People with active epilepsy using NABs more commonly have CCDs. NAB use is associated with CCD, whereas active epilepsy is not.

Indexed as

AnticonvulsantsArrhythmias, CardiacEpilepsyHeart Conduction SystemSodium Channel BlockersAgedAged, 80 and overAgingCanadaCross-Sectional StudiesElectrocardiographyFemaleHumansLongitudinal StudiesMaleMiddle AgedAnticonvulsantsPhenytoinSodium Channel Blockers

Identifiers

PMID39899787
PMCPMC11793923

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.